Get to know our clinical trials

Phase II clinical study to evaluate the safety and efficacy of Telisotuzumab Adizutecan in the treatment of subjects with locally advanced or metastatic solid tumors with MET amplification.

THE AIM OF THIS STUDY IS TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF TEMAB-A AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MET GENE AMPLIFICATION.

Imagen de la Dra. Ana Landa Magdalena, especialista en Oncología Médica de la Clínica Universidad de Navarra. La Dra. Landa se dedica preferencialmente a los ensayos clínicos y tumores de páncreas y vía biliar.
Dr. Ana Landa Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Gastrointestinal Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TELISOTUZUMAB ADIZUTECAN IN THE TREATMENT OF SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH MET AMPLIFICATION.
  • Code EudraCT: 2024-518871-74-00
  • Protocol number: M25-279
  • Promoter: Abbvie
  • Molecule/Drug: Telisotuzumab Adizutecan
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION